Attorney Docket No.:

ISPH-0543

Serial No.:

09/851,871

Page 4

REMARKS

Claims 1-12 are pending in the instant application. All of the claims have been

rejected. Claim 1 has been amended. Claims 13-14 were cancelled in a previous

amendment. No new matter has been added by this amendment. Reconsideration is

respectfully requested in light of the amendment and the following remarks.

I. Rejection of Claims Under 35 U.S.C. 112, paragraph 1

Claims 1-12 were rejected for containing matter which was not described in the

specification. The Examiner has objected to the inclusion of Genbank numbers based on

the teachings of non-patent documents that were stated to be incorporated by reference

into the specification.

The Applicants have amended the claims to recite Genbank numbers that were

listed in the original specification.

In view of the amendment, the Applicants submit that all of the matter in the claims

is fully supported by the specification and the rejection of the claims under 35 U.S.C. 112,

paragraph 1 is traversed.

II. Fees

The Applicants hereby request that the Commissioner charge Deposit Account No.

500252 the fee of \$790.00 for the filing of a Request for Continued Examination, Large

Entity. It is believed that no further fee is due. However, if an additional fee is due, the

Commissioner is hereby entitled to charge the fee to the Deposit Account listed above

citing Reference No. ISPH-0543.

Attorney Docket No.:

ISPH-0543

Serial No.:

09/851,871

Page 5

III. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.

Respectfully submitted,

Colleen J. McKiernan, PhD Registration No. 48,570

Date: January 3, 2005

Isis Pharmaceuticals 2922 Faraday Avenue Carlsbad, CA 92008

Phone: 760-603-2722 Facsimile: 760-603-3820